ยินดีต้อนรับกลับมา
เข้าร่วม CoinTime
เข้าสู่ระบบ email
สร้างบัญชี email
ตรวจสอบกล่องจดหมายของคุณ
Syndax Pharmaceuticals
About
Syndax Pharmaceuticals focuses on developing an HDAC inhibitor for solid tumors and hematological tumors.
- 101 - 250
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $30M
- Industries
- Biotechnology,Clinical Trials,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2005
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 31, 2020 | Post-IPO Debt | $30M | 2 |
Hercules Capital
|
— | Detail |
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Jul 1, 2021
prePO
|
Seed | $1.10M | Blockchain | — |
|
Mar 20, 2019
Commonwealth Labs
|
Seed | $2M | Cryptocurrency | Yes |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hercules Capital
|
Yes | Post-IPO Debt |
|
|
Yes | Post-IPO Debt |
